Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsTYPTF 12-1 Month Momentum % is 1.82% as of Jul. 25, 2026. The stock has 5 warning signs investors should review. Among 1,361 Biotechnology companies, Entropy Neurodynamics ranks better than 59.74% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-25), Entropy Neurodynamics's 12-1 Month Momentum % is 1.82%.
The industry rank for Entropy Neurodynamics's 12-1 Month Momentum % or its related term are showing as below:
TYPTF's 12-1 Month Momentum % is ranked better than 59.74% of 1361
companies
in the Biotechnology industry
Industry Median: -18.13
vs TYPTF: 1.82
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Entropy Neurodynamics 12-1 Month Momentum % Related Terms
TYPTF vs VRTX, REGN, ALNY: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a 12-1 Month Momentum % of 1.82% as of Jul. 25, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #548 out of 1361 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Entropy Neurodynamics' 12-1 Month Momentum % too high?
Entropy Neurodynamics' current 12-1 Month Momentum % is 1.82%. Based on the distribution chart, Entropy Neurodynamics ranks #548 out of 1361 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #548 out of 1361 companies for 12-1 Month Momentum %. This puts Entropy Neurodynamics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current 12-1 Month Momentum % is 1.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current 12-1 Month Momentum % is 1.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current 12-1 Month Momentum % is 1.82% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 
